Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B-cell lymphoma: Insights from real-life clinical practice.

ABSTRACT:

Background

Tumor lysis syndrome (TLS) is a potentially life-threatening condition resulting from the rapid destruction of malignant cells, leading to electrolyte imbalances and severe complications, such as acute kidney injury, arrhythmias, and seizures. TLS can be managed through hyperhydration, urate-lowering treatments, and a steroid prophase strategy.

Aims

This study aims to explore the impact of fractionated rituximab, an anti-CD20 antibody, on the occurrence and severity of TLS during the initial cycle in patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL).

Methods

Data was retrospectively collected from 94 of 186 patients.

Results

Among the 94 patients included in the analysis, the median age was 70. Histologies were diffuse large B-cell lymphom

SUBMITTER: Mohamad J 

PROVIDER: S-EPMC11480531 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature